Left Menu
Development News Edition

Study reveals how exactly an investigational drug stops coronavirus

According to the findings published in the Journal of Biological Chemistry, remdesivir blocks a particular enzyme, RNA-dependent RNA polymerase, that is required for genome replication of the virus.

Devdiscourse News Desk | Alberta | Updated: 28-02-2020 09:59 IST | Created: 28-02-2020 09:43 IST
Study reveals how exactly an investigational drug stops coronavirus
Gilead has initiated two Phase III clinical trials to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19.  Image Credit: ANI

The novel coronavirus outbreak, a new strain of previously unidentified coronavirus in humans is rapidly spreading around the world, claiming more than 2,700 lives in China alone. As of now, there is no specific cure or vaccine for the virus, however, an investigational new drug developed by US biotech firm Gilead Sciences is being evaluated for the treatment of novel coronavirus, aka COVID-19.

A team of academic and industry researchers from the University of Alberta and Gilead Sciences have published new findings about how Remdesivir actually works in coronavirus patients. The investigational drug has demonstrated a potential activity in animal models against the viral pathogens Middle-East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS), which are also coronaviruses.

According to the new findings, remdesivir blocks a particular enzyme, i.e. RNA-dependent RNA polymerase required for genome replication of the virus. Once the drug is incorporated into the growing RNA chain, the virus can no longer replicate.

"Even if you know a drug works, it can be a red flag if you don't know how it works, " said Matthias Götte, a virologist and professor at the University of Alberta, Edmonton, who led the JBC study.

"We know the drug works against different coronaviruses, like MERS and SARS, and we know the novel coronavirus is very similar to SARS. So I would say I'm cautiously optimistic that the results our team found with remdesivir and MERS will be similar with COVID-19," he further added.

Götte said more than one drug will be needed to properly fight emerging diseases like COVID-19, as with HIV and hepatitis C virus infections. The team is now waiting for results from ongoing clinical trials with remdesivir, which are expected by the end of April 2020.

Following the U.S. Food and Drug Administration's (FDA) rapid review and acceptance of its investigational new drug (IND) filing, Gilead has initiated two Phase III clinical trials to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19.

Gilead said on Thursday that the new clinical studies expand the ongoing research into remdesivir, which includes two clinical trials in China's Hubei province led by the China-Japan Friendship Hospital as well as the recently initiated clinical trial in the United States led by the National Institute of Allergy and Infectious Diseases (NIAID).

Gilead's primary focus is on rapidly determining the safety and efficacy of remdesivir as a potential treatment for COVID-19, and this complementary array of studies helps to give us a more expansive breadth of data globally on the drug's profile in a short amount of time.

Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.

Gilead developed remdesivir as a response to the 2014 West African Ebola virus epidemic. The investigational drug is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for any use.

The study published in the Journal of Biological Chemistry was funded by the Canadian Institutes of Health Research and the Alberta Ministry of Economic Development, Trade and Tourism.

Download The Devdiscourse News App for Latest News.


TRENDING

OPINION / BLOG / INTERVIEW

Maritime transport post-COVID 19: Disruptions ahead in business models, techno-investments, regulations

Cargo shipping is a crucial part of the global supply chains and is likely to become more resilient along with efforts to make supply chains resilient but cruise liners could face much more disruptive changes....

Asia-Pacific response to COVID-19 and climate emergency must build a resilient and sustainable future

... ...

Videos

Latest News

Efforts to contain desert locusts in East Africa forging ahead despite COVID-19

Sustained efforts to contain East Africas worst invasion of desert locusts in decades are forging ahead, despite limits on the flow of personnel and equipment stemming from the global COVID-19 pandemic, the UN food agency said Friday. The i...

U.S. Congress in talks on coronavirus small business aid after partisan clash

A partisan skirmish in the U.S. Senate cut short a Republican effort to speed 250 billion in new assistance to small businesses on Friday, forcing Republicans and Democrats to negotiate over how best to help independent firms reeling from t...

Once the biggest outbreak outside of China, S.Korean city reports zero new coronavirus cases

The South Korean city of Daegu, which endured the first large coronavirus outbreak outside of China, on Friday reported zero new cases for the first time since late February, as new infections across the country dropped to record lows. With...

Women’s rights made over decades in danger due to COVID-19: UN chief

Limited gains in gender equality and womens rights made over the decades are in danger of being rolled back due to the COVID-19 pandemic, the UN Secretary-General said on Thursday.The dire warning from Antnio Guterres is laid out in a polic...

Give Feedback